Tempest Therapeutics Announces New Leadership and Acquisition

Tip Ranks
2025.11.19 14:49
portai
I'm PortAI, I can summarize articles.

Tempest Therapeutics announced an Asset Purchase Agreement with Erigen LLC and Factor Bioscience Inc. for CAR T-cell therapies, expected to close in early 2026. Dr. Matt Angel will become CEO and President. The deal involves shares and warrants, pending stockholder approval. Analysts rate TPST stock as Hold with a $9.00 target, but TipRanks’ AI Analyst views it as Underperform due to financial challenges and bearish technical analysis. The stock is high risk with potential high reward.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Tempest Therapeutics ( (TPST) ) has shared an announcement.

Tempest Therapeutics, Inc. has entered into an Asset Purchase Agreement with Erigen LLC and Factor Bioscience Inc., involving the acquisition of assets related to CAR T-cell therapies. The transaction, expected to close in early 2026, will result in significant changes in the company’s leadership, with Dr. Matt Angel appointed as CEO and President. The deal includes the issuance of shares and warrants, and is subject to stockholder approval and other conditions.

The most recent analyst rating on (TPST) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Tempest Therapeutics stock, see the TPST Stock Forecast page.

Spark’s Take on TPST Stock

According to Spark, TipRanks’ AI Analyst, TPST is a Underperform.

Tempest Therapeutics scores low primarily due to its financial performance, marked by a lack of revenues and high expenditures, leading to ongoing losses. The technical analysis indicates a bearish trend, further impacting the score. Valuation metrics are challenging to apply due to the negative earnings, typical for its growth stage. Overall, the stock presents high risk with potential for high reward contingent on future developments.

To see Spark’s full report on TPST stock, click here.

More about Tempest Therapeutics

Average Trading Volume: 46,434

Technical Sentiment Signal: Sell

Current Market Cap: $41.65M

For a thorough assessment of TPST stock, go to TipRanks’ Stock Analysis page.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.